Shares of Enovix Corporation (NASDAQ:ENVX - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $2.35 and last traded at $2.3850, with a volume of 12,335,264 shares traded. The stock had previously closed at $2.51.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. Loop Capital raised shares of Enovix to a "strong-buy" rating in a research note on Monday, August 17th. B. Riley Financial dropped their price target on Enovix from $10.00 to $9.00 and set a "buy" rating for the company in a research note on Thursday, August 13th. Canaccord Genuity Group dropped their price target on Enovix from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of Enovix in a report on Thursday, August 13th. Finally, William Blair lowered Enovix from an "outperform" rating to a "market perform" rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.77.
Check Out Our Latest Report on Enovix
Enovix Stock Performance
The company has a current ratio of 9.71, a quick ratio of 9.37 and a debt-to-equity ratio of 2.46. The company's 50-day simple moving average is $3.29 and its 200-day simple moving average is $5.07. The stock has a market capitalization of $529.97 million, a price-to-earnings ratio of -2.97 and a beta of 2.49.
Enovix (NASDAQ:ENVX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The company had revenue of $9.02 million for the quarter, compared to analyst estimates of $8.43 million. Enovix had a negative net margin of 473.89% and a negative return on equity of 64.50%. Enovix's revenue was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) earnings per share. Enovix has set its Q3 2026 guidance at -0.170--0.130 EPS. On average, analysts expect that Enovix Corporation will post -0.80 EPS for the current year.
Institutional Investors Weigh In On Enovix
Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in Enovix during the fourth quarter valued at $30,000. Sequoia Financial Advisors LLC bought a new position in shares of Enovix in the 2nd quarter worth about $61,000. Sax Wealth Advisors LLC bought a new position in shares of Enovix in the 3rd quarter worth about $29,000. Calamos Advisors LLC acquired a new position in shares of Enovix in the 1st quarter valued at about $60,000. Finally, Allworth Financial LP acquired a new position in shares of Enovix in the 2nd quarter valued at about $71,000. Institutional investors own 50.92% of the company's stock.
About Enovix
(
Get Free Report)
Enovix Corporation is a battery technology company developing lithium-ion batteries that use a silicon-based anode and a three-dimensional cell architecture. The company's design is intended to increase energy density while incorporating structural features designed to improve safety and cycle life compared with conventional lithium-ion batteries.
Enovix is focused initially on batteries for consumer electronics, including smartphones, wearable devices and other mobile products. It has also identified applications in industrial, medical, aerospace, defense and electric vehicle markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enovix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.
While Enovix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.